After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease

As Biogen stays in the hunt for an Alzheimer’s treatment with the recent presentation of data about aducanumab made at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference on December 5, it’s expanding its pipeline.

Ionis Pharmaceuticals, based in Carlsbad, California, announced it had licensed its IONIS-MAPTRX to Biogen.